Hepatocyte Sirtuin 6 Protects against Atherosclerosis and Steatohepatitis by Regulating Lipid Homeostasis
Cells · 05.08.2023 · 12 (15) · 2009
DOI: 10.3390/cells12152009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 05.08.2023. Verfasst von Yingdong Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Sirtuins, Atherosclerosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Histone deacetylase Sirtuin 6 (SIRT6) regulates many biological processes. SIRT6 is known to regulate hepatic lipid metabolism and inhibit the development of nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the role of hepatocyte SIRT6 in the development of atherosclerosis and further characterize the mechanism underlying SIRT6’s effect on NAFLD. Ldlr−/− mice overexpressing or lacking hepatocyte SIRT6 were fed a Western diet for 16 weeks. The role of hepatic SIRT6 in the development of nonalcoholic steatohepatitis (NASH), atherosclerosis, and obesity was investigated. We also investigated whether p53 participates in the pathogenesis of NAFLD in mice overexpressing hepatic SIRT6. Our data show that loss of hepatocyte SIRT6 aggravated the development of NAFLD, atherosclerosis, and obesity in Ldlr−/− mice, whereas adeno-associated virus (AAV)-mediated overexpression of human SIRT6 in the liver had opposite effects. Mechanistically, hepatocyte SIRT6 likely inhibited the development of NAFLD by inhibiting lipogenesis, lipid droplet formation, and p53 signaling. Hepatocyte SIRT6 also likely inhibited the development of atherosclerosis by inhibiting intestinal lipid absorption and hepatic VLDL secretion. Hepatic SIRT6 also increased energy expenditure. In conclusion, our data indicate that hepatocyte SIRT6 protects against atherosclerosis, NAFLD, and obesity by regulating lipid metabolism in the liver and intestine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
- School of Biomedical Sciences, Kent State University, Kent, OH 44240, USA.
ORCID-Profile: Xiaoli Pan, Raja Gopoju, Yanyong Xu, Yanqiao Zhang
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Zhu, Y., Hu, S., Pan, X., Gopoju, R., Cassim Bawa, F. N., Yin, L., Xu, Y., & Zhang, Y. (2023). Hepatocyte Sirtuin 6 Protects against Atherosclerosis and Steatohepatitis by Regulating Lipid Homeostasis. Cells, 12(15), 2009. https://doi.org/10.3390/cells12152009
Vancouver
Zhu Y, Hu S, Pan X, Gopoju R, Cassim Bawa FN, Yin L, et al. Hepatocyte Sirtuin 6 Protects against Atherosclerosis and Steatohepatitis by Regulating Lipid Homeostasis. Cells. 2023;12(15):2009. doi:10.3390/cells12152009
BibTeX
@article{Zhu2023,
author = {Zhu, Yingdong and Hu, Shuwei and Pan, Xiaoli and Gopoju, Raja and Cassim Bawa, Fathima N and Yin, Liya and Xu, Yanyong and Zhang, Yanqiao},
title = {Hepatocyte Sirtuin 6 Protects against Atherosclerosis and Steatohepatitis by Regulating Lipid Homeostasis},
journal = {Cells},
year = {2023},
volume = {12},
number = {15},
pages = {2009},
doi = {10.3390/cells12152009}
}
EUVIMED